Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao IRIS UNIMORE - Archi...arrow_drop_down
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
addClaim

Aprepitant as anticancer drug

Authors: MICHAEL KHUN; PEER BORK; COSTI, Maria Paola; LUCIANI, Rosaria;

Aprepitant as anticancer drug

Abstract

The present invention relates to the use of a heterocyclic compound according to generalstructural formula (I) for the treatment of cancer. In a preferred aspect the compound according 5to formula (I) is aprepitant.BACKGROUND OF THE INVENTIONCancer is a disorder in which a population of cells has become, in varying degrees, unresponsive 10to the control mechanisms that normally govern proliferation and differentiation. Therapeuticagents used in clinical cancer therapy can be categorized into several groups, including,alkylating agents, antibiotic agents, antimetabolic agents, biologic agents, hormonal agents, andplant-derived agents.15Cancerous cells display uncontrolled growth (growth and division beyond the normal limits),invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread toother locations in the body via lymph or blood). Much effort has been spent to find novel anticanceragents. Cancer therapy is also being attempted by modulating the enzymatic activity oftarget proteins in cancer cells. For example, compounds were found which inhibit enzymes used 20in purine and pyrimidine synthesis such as thymidylate synthase (TS), dihydrofolate reductase(DHFR), and glycinamide ribonucleotide formyl transferase (GARFT). By inhibiting theformation of precursor purine and pyrimidine nucleotides, the formation of DNA and RNA iscomprimised, which are necessary for the growth and survival of both normal cells and cancercells. As cancer cells are rapidly dividing they heavily rely on a sufficient supply of nucleotides 25to afford such rapid divisions. However, therapeutic target proteins, such as the aforementionedenzymes respond differently to treatment depending on the type of cancer and the the geneticpredisposition of the patient.Due to the multiple different forms of cancer there is a need for additional pharmaceutically 30active substances which can be used to treat cancer.SUMMARY OF THE INVENTION2The inventors have identified a compound which unexpectedly is useful to effectively treatcancer.

Country
Italy
Keywords

Aprepitant; antifolates; dhydrofolate reductase; anticancer

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
    OpenAIRE UsageCounts
    Usage byUsageCounts
    visibility views 40
  • 40
    views
    Powered byOpenAIRE UsageCounts
Powered by OpenAIRE graph
Found an issue? Give us feedback
visibility
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
views
OpenAIRE UsageCountsViews provided by UsageCounts
0
Average
Average
Average
40
Related to Research communities
Cancer Research
Upload OA version
Are you the author of this publication? Upload your Open Access version to Zenodo!
It’s fast and easy, just two clicks!